Motiva Breast Implants and BII: What to Know in 2026
Making the decision to get breast implants is a significant personal journey. If you’re exploring breast augmentation, our Denver guide covers candidacy, implant choices, and recovery. It’s a path filled with questions about aesthetics, results, and most importantly, safety. Two topics that often come up are the innovations of newer devices like Motiva breast implants and BII (Breast Implant Illness), a collection of symptoms some women experience.
Understanding these complex subjects is key to feeling confident and empowered in your choice. This guide breaks down everything you need to know, from advanced implant technology to the latest safety protocols, so you can have an informed conversation about your health and goals.
The Safety and Performance of Motiva Implants
When considering any implant, the first questions are always about safety and complication rates. Motiva implants, a newer generation of silicone gel implants, have been used internationally since 2010 and are known for their strong safety profile.
A major 2023 meta analysis of 4,784 patients found a low overall complication rate of just 5.2% with Motiva’s SmoothSilk® surface. One of the most common long‑term concerns, capsular contracture (the hardening of scar tissue around the implant), which sometimes requires revision breast augmentation, was seen in only about 0.5% of cases in short‑ to mid‑term follow‑up. This is a significant improvement compared to some traditional implants, which can have rates closer to 10% or more over time. Even better, in that same large patient group, there were zero reported cases of BIA ALCL, the rare lymphoma linked to some implants. The manufacturer reports that with over 3 million implants placed worldwide, device related complications leading to reoperation are less than 1%.
Why Is Breast Implant Illness (BII) So Hard to Pinpoint?
Breast Implant Illness, or BII, is the term patients use for a wide range of systemic symptoms they believe are connected to their implants. These can include fatigue, joint pain, brain fog, and autoimmune like issues. One of the biggest challenges in understanding the link between motiva breast implants and bii is that BII is not yet an official medical diagnosis.
Currently, there is no specific ICD 10 code, the standardized system doctors use for diagnoses. Without a code, it’s incredibly difficult to track cases in medical records or conduct large scale public health studies. This lack of a formal diagnosis makes it very hard to measure how often BII truly happens, which is a source of frustration for patients seeking validation and care. Patient advocacy groups have petitioned for a code to be created, which would help legitimize patient experiences and fuel more structured research.
Motiva’s Design: A Focus on Reducing Inflammation
A key feature of Motiva implants is their unique outer shell, called the SmoothSilk® or SilkSurface®. This is an ultra smooth nanosurface, meaning its texture is incredibly fine, much smoother than traditional textured implants.
Why does this matter? Research suggests that rougher implant surfaces can create more friction and irritation for the body’s tissues. This can lead to a chronic inflammatory response and the formation of biofilm, a slimy layer of bacteria that can hide in the nooks of a textured surface. This chronic inflammation is believed to be a trigger for complications like capsular contracture and has been linked to BIA ALCL.
The ultra smooth surface of Motiva implants is designed to be more biocompatible, meaning it interacts more gently with the body. Studies show that this smoother surface leads to less inflammation and fibrosis (scar tissue). This likely explains the very low rates of capsular contracture seen with Motiva. By minimizing the potential for chronic irritation, this design aims to get the best of both worlds: the benefits of a stable implant with a much lower risk profile.
Do Motiva Implants Lower the Risk of BII?
This is a common question when discussing motiva breast implants and bii. The honest answer is that we don’t know for sure. Since the exact cause of BII is still being researched, no implant can claim to prevent it.
However, the design philosophy behind Motiva targets factors that some experts believe could contribute to BII. By creating a shell that reduces chronic inflammation and has a barrier layer to minimize silicone gel bleed, Motiva aims to create a quieter, more harmonious relationship with the body. While it’s plausible this could lead to fewer BII cases, there isn’t enough long term clinical data to make a definitive claim. The FDA acknowledges that any breast implant can be associated with systemic symptoms in some women.
If you have concerns about BII, an open conversation with an experienced surgeon is crucial. At Leela Mundra MD, we believe in a fully transparent approach, helping you weigh the pros and cons of all your options. You can schedule a consultation to discuss your personal health history and goals in a supportive environment.
The FDA and Patient Safety Checklists
In the United States, Motiva implants are FDA approved.
To enhance patient safety for all implants, the FDA has also implemented two critical tools:
The Boxed Warning: Often called a black box warning, this is a clear, mandatory statement on all breast implant literature. It informs patients that implants are not lifetime devices, that complication risks can increase over time, and that additional surgeries may be necessary.
The Patient Decision Checklist: Before surgery, your surgeon must review a detailed checklist with you. This document ensures you have discussed everything from the risks of BIA ALCL and systemic symptoms (BII) to the alternatives to implants, such as a breast lift. Both you and your surgeon sign it, confirming you’ve had a thorough informed consent conversation.
BIA ALCL vs. BII: Understanding the Difference
It is vital to distinguish between BIA ALCL and BII, as they are completely different conditions.
BIA ALCL is a rare, treatable cancer of the immune system, not breast cancer. It develops in the scar tissue around an implant, often years later. It is overwhelmingly linked to older, more aggressively textured implants. With smooth surface implants like Motiva, the risk is considered extremely low, with no confirmed cases to date.
BII is not a cancer but a collection of patient reported symptoms. Its cause is unknown, and it has been reported by women with all types of implants, including silicone and saline.
Monitoring for these is also different. For BIA ALCL, patients should watch for any late onset swelling or lumps. For BII, monitoring involves paying attention to your overall health and reporting any new, persistent systemic symptoms to your doctor.
Enhancing Safety with Technology and Registries
Modern breast implants are incorporating technology to improve long term safety. Motiva offers an optional feature called Q Inside Safety Technology, a tiny, FDA cleared RFID microtransponder inside the implant. This allows a doctor to scan the implant and instantly retrieve its serial number, model, and size without surgery. This is invaluable for tracking and in the rare event of a device recall.
Furthermore, breast implant registries, like the National Breast Implant Registry (NBIR) in the U.S., play a crucial role. These secure databases collect de identified data on implant procedures and outcomes. By analyzing data from thousands of patients, registries help researchers spot trends, identify risks like BIA ALCL, and better understand complex issues like BII. Contributing your data to a registry is a simple way to help improve safety for all women in the future. For an overview of implant safety and recovery, explore our patient education videos.
Choosing a surgeon who is committed to these long term safety practices is essential. In our Denver practice, and as we plan our expansion to Tampa and St. Petersburg, FL, our commitment is to provide a lifetime of support for our patients. If you’re ready to learn more, we invite you to contact our office.
Frequently Asked Questions About Motiva Breast Implants and BII
1. What makes Motiva implants different from other silicone implants?
Motiva implants are known for their SmoothSilk® nanosurface, which is designed to be highly biocompatible. This ultra smooth surface may reduce the body’s inflammatory response, leading to significantly lower rates of capsular contracture and potentially lowering other risks associated with chronic inflammation.
2. Can I still get Breast Implant Illness with Motiva implants?
Yes, it is possible. BII has been reported by women with every type of breast implant on the market. While Motiva’s design aims to minimize potential triggers like inflammation, no implant can guarantee prevention of BII. This makes the topic of motiva breast implants and bii an important one to discuss with your surgeon.
3. Is BIA ALCL a major concern with Motiva implants?
The risk of BIA ALCL with smooth surface implants like Motiva is exceptionally low. The vast majority of BIA ALCL cases have been linked to implants with more aggressive texturing. To date, there have been no confirmed cases of BIA ALCL with Motiva implants.
4. Are Motiva implants FDA approved in the U.S.?
As of 2024, Motiva implants is FDA approved! They are approved for use in more than 90 countries.
5. What should I do if I think I have BII symptoms?
If you have breast implants and are experiencing unexplained symptoms like chronic fatigue, joint pain, or brain fog, the first step is to speak with your plastic surgeon and your primary care physician. They can conduct a thorough medical workup to rule out other causes and discuss your options, which may include implant removal.